Objective: Controversy persists surrounding the perceived bleeding risk associated with perioperative clopidogrel use in patients undergoing lower extremity bypass (LEB). The purpose of this study was to examine the LEB bleeding risk and clinical sequelae associated with clopidogrel.
Results: Among the LEB cohort (N ¼ 9179), 28% (n ¼ 2544) were taking clopidogrel and 72% (n ¼ 6635) were not. Patients taking clopidogrel were more likely to have coronary disease, prior coronary intervention, abnormal findings on stress test, and aspirin use (P < .001 for all). Patients taking clopidogrel were more likely to receive blood transfusion (38% vs 24%; P < .001) and to have estimated blood loss $500 mL (21% vs 12%; P < .001). Reoperation for bleeding rates were similar (0.9% vs 1.1%; P ¼ .9). Clopidogrel use was also associated with increased mean operative times (244 minutes vs 232 minutes; P < .001) as well as with cardiac complications (8.8% vs 6.5%; P ¼ .001), respiratory complications (2.5% vs 1.6%; P ¼ .007), and in-hospital mortality (1.3% vs 0.8%; P ¼ .03). Multivariable analysis demonstrated that clopidogrel was associated with increased risk of 1-or 2-unit blood transfusion (odds ratio [OR], 1.8; 95% confidence interval [CI], 1.5-2.1; P < .001) and >2-unit blood transfusion (OR, 2.0; 95% CI, 1.7-2.5; P < .001). Major cardiac events (OR, 1.2; 95% CI, 1.0-1.5; P ¼ .05) and respiratory complications (OR, 1.4; 95% CI, 1.0-2.0; P ¼ .03) were also independently associated with clopidogrel use. Weighted Mantel-Haenszel ORs controlling for blood transfusion amount revealed no remaining effect of clopidogrel on major cardiac events (OR, 1.1; P ¼ .4) or respiratory complications (OR, 1.0; P ¼ .8).
Conclusions: Perioperative clopidogrel use in LEB surgery is associated with increased blood loss and blood transfusion. Associated clinical sequelae include increased cardiac and pulmonary complications. Accordingly, surgeons should consider discontinuation of perioperative clopidogrel when it is clinically appropriate unless it is strongly indicated at the time of LEB. (J Vasc Surg 2017; 65:1719-28.) Many patients who undergo surgical lower extremity revascularization have concurrent coronary or carotid atherosclerosis, for which they take clopidogrel, either alone or as a component of dual antiplatelet therapy (aspirin and clopidogrel). In such patients, discontinuation of clopidogrel before lower extremity bypass (LEB) may expose patients to increased risk of thrombotic complications in the perioperative period. 1 Alternatively, continuing clopidogrel may lead to increased bleeding complications. A lack of clear data describing the competing risks associated with clopidogrel use has led to wide variation in its perioperative management. Additional material for this article may be found online at www.jvascsurg.org. To address concerns about the safety of continuing clopidogrel at the time of surgery, it has previously been shown that LEB can be safely performed without incurring increased risk of reoperation for bleeding or other severe bleeding complications. 2, 3 Initiation of clopidogrel in the postoperative period may even be beneficial, as its use is associated with improved patency in prosthetic LEB. 3 However, perceptions of increased bleeding risk persist, and many surgeons choose to discontinue clopidogrel preoperatively. These concerns have been substantiated by conflicting data showing that clopidogrel use may lead to an increase in perioperative blood transfusions. [2] [3] [4] Importantly, blood transfusions are not clinically inconsequential as they have previously been associated with major perioperative morbidity and mortality among vascular surgery patients. [4] [5] [6] [7] [8] As a result, a decrease of blood transfusion rates has become an objective goal to improve quality of care in the LEB patient. 4, 8 The purpose of this study was to determine the bleeding risk associated with perioperative clopidogrel use at the time of LEB. Furthermore, we sought to describe the clinical implications of differences in bleeding risk associated with clopidogrel use.
METHODS
Database and cohort assembly. A retrospective analysis of all patients undergoing infrainguinal LEB from 2008 to 2014 in the Vascular Quality Initiative (VQI) database was performed. The VQI is currently used by approximately 370 centers and 2800 physicians. Clinical sites participating in the VQI registry enter data regarding characteristics of the patients, operative details, and outcomes encompassing >150 variables. The database undergoes annual clinical audits using hospital claims data to ensure that all procedures are entered by participating sites. 9, 10 The VQI contains deidentified patient data, and consequently, consent and Institutional Review Board approval are not applicable. Only the initial LEB was studied for each patient. To study patients undergoing elective LEB for atherosclerotic disease, emergency cases and patients with acute limb ischemia or aneurysmal disease as the indication for LEB were excluded. Patients undergoing concurrent suprainguinal bypass or endovascular intervention were also excluded. All patients had bypass origin at the common femoral artery or lower and target at the aboveknee popliteal artery or lower. With regard to conduit, only autologous vein and standard prosthetic were studied. Patients who were receiving long-term oral anticoagulation at any time within 30 days before surgery were also excluded as the database contains no information on how anticoagulation was managed perioperatively.
Exposure and outcome measures. Patients were first categorized by clopidogrel medication use. In the VQI, perioperative antiplatelet medications are recorded on the basis of whether the patient received the medication within the 36 hours before surgery. A very small number of patients (0.6% of the sample) who were taking antiplatelet medications other than aspirin or clopidogrel (prasugrel, ticlopidine, ticagrelor, or "other") were excluded.
Characteristics of the patients and operative details were compared between patients who received clopidogrel within 36 hours of LEB and those who did not, regardless of aspirin use. Preoperative hemoglobin measurements were available for 98.8% of patients. Preoperative anemia was defined as hemoglobin level <13 g/dL in men or <12 g/dL in women. 4 
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Study Group of New England Cardiac Risk Index (VSG-CRI) scores were calculated for patients to determine preoperative cardiac risk.
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The primary outcomes studied were perioperative blood transfusion (0 units, 1-2 units, $3 units), estimated blood loss (EBL) $500 mL, and reoperation for bleeding. Blood transfusion is reported as the total number of units given in the preoperative, intraoperative, or postoperative period during the index hospitalization. Approximately 1.6% of patients had no transfusion data and were excluded.
Secondary outcomes were defined in the perioperative period as mean procedure time, major cardiac event (myocardial infarction, dysrhythmia, or new-onset congestive heart failure), 11 respiratory complication (pneumonia or reintubation), wound infection, graft infection, ipsilateral major amputation, graft occlusion at discharge, and in-hospital mortality. 
Recommendation:
The authors suggest that clopidogrel be discontinued before lower extremity bypass to minimize bleeding and associated complications, if it is safe to do so. perioperative blood transfusion in two separate models: 1 or 2 units vs 0 units and >2 units vs 0 units. This categorization was based on previously reported analyses and was intended to determine the strength of association of different predictors with blood transfusion based on transfusion amount. 5 In addition, distinct multivariable logistic regression models were constructed to determine factors predictive of major cardiac events and respiratory complications among all LEB patients. Multivariable models included characteristics of the patients (demographics, comorbidities, and perioperative medications) and operative factors. All variables that were statistically significantly different on univariate analysis were considered for inclusion in multivariable models, as were clinically meaningful variables. Centers exhibited variation with regard to how often patients undergoing LEB were taking clopidogrel. Among the 160 centers studied, the median proportion of patients taking clopidogrel at the time of LEB was 33.3% (interquartile range, 21.8-43.7). Similarly, variation was evident in the proportion of patients receiving blood transfusions. The median proportion of patients receiving blood transfusions was 22.2% (interquartile range, 1.1-35.4). Despite these differences in management of clopidogrel and perioperative blood transfusions, centers did not exhibit correlation in their likelihood to operate on patients taking clopidogrel and their likelihood to administer perioperative blood transfusions (Pearson correlation coefficient ¼ 0.12; P ¼ .1). Centers that were more likely to operate on patients taking clopidogrel were not also statistically more likely to administer blood transfusion. To account for center-level variation in multivariable models, cluster standard errors accounting for intragroup correlation (for clustering effects of patients within each center) were used.
To determine whether blood transfusion was affecting the relationship between clopidogrel use and select secondary outcomes, analyses were stratified by blood transfusion amount. Mantel-Haenszel methods were used to compute combined odds ratios (ORs) weighted to account for blood transfusion amount. To further account for confounding of transfusion outcomes at a center level, centers were stratified into terciles on the basis of their likelihood to operate on patients taking clopidogrel (low clopidogrel use, medium clopidogrel use, and high clopidogrel use). Combined MantelHaenszel ORs were then calculated to describe the effect of clopidogrel use on blood transfusion while accounting for the center's likelihood to operate on patients taking clopidogrel. All P values are two tailed and were considered statistically significant if < .05. Data were analyzed using Stata version 14.1 (StataCorp, College Station, Tex).
RESULTS
Characteristics of patients and operative factors. Of 9179 LEBs, 28% (n ¼ 2544) were performed on patients taking clopidogrel and 72% (n ¼ 6635) were performed on patients not taking clopidogrel. Overall, 69% of LEBs were performed for critical limb ischemia with no difference between groups. There were multiple other demographic differences based on clopidogrel use (Table I) . In particular, patients taking clopidogrel had higher rates of comorbid cardiovascular conditions including coronary artery disease, prior coronary artery bypass graft or coronary intervention, hypertension, congestive heart failure, and abnormal findings on stress test. This resulted in a distribution of patients with higher VSG-CRI scores in patients taking clopidogrel (mean score, 3.2 6 1.8) compared with those who were not (mean score, 3.0 6 1.8; P < .001). Patients taking clopidogrel also had higher rates of diabetes and hemodialysis dependence. Notably, patients taking clopidogrel had lower documented preoperative hemoglobin level (12.1 g/dL vs 12.6 g/dL; P < .001), resulting in higher rates of preoperative anemia (57% vs 48%; P < .001). Patients taking clopidogrel were also more likely to be taking preoperative aspirin, beta blockers, and statins (P < .001 for all).
Univariate analysis of technical details demonstrated that patients taking clopidogrel were more likely to undergo LEB with prosthetic conduit (32% vs 29%; P ¼ .003; Table I ). In addition, clopidogrel patients were more likely to have a common femoral artery origin (73% vs 69%; P ¼ .001) and slightly more likely to have a vertical groin incision (68% vs 65%; P ¼ .004).
Univariate analysis of outcomes. Univariate analysis showed that patients taking clopidogrel perioperatively were more likely to receive blood transfusions, with 16% of patients taking clopidogrel receiving >2 units compared with 8.6% of patients who were not (P < .001; Table II ). For the other primary outcomes, patients taking clopidogrel had higher proportion of patients with EBL $ 500 mL (21% vs 12%; P < .001) but no difference in reoperation for bleeding. For secondary outcomes, patients taking clopidogrel had longer procedure times (244 minutes vs 232 minutes; P < .001) and were more likely to suffer a major cardiac event (8.8% vs 6.5%; P < .001) or respiratory complication (2.5% vs 1.6%; P ¼ .002). Patients taking clopidogrel also demonstrated higher in-hospital perioperative mortality (1.3% vs 0.8%; P ¼ .03).
Multivariable models. Multivariable analysis was first performed to predict perioperative blood transfusion of 1 or 2 units compared with 0 units. Clopidogrel use was found to be independently associated with 1-to 2-unit blood transfusion (OR, 1.8; 95% confidence interval [CI], 1.5-2.1; P < .001; Table III) . Notably, aspirin use had no effect. Preoperative anemia was found to be the most predictive factor (OR, 3.6; 95% CI, 3.2-4.2; P < .001). Multiple other demographic and operative factors were also predictive of blood transfusion. A similar multivariable analysis was performed to determine which factors were predictive of blood transfusion of >2 units compared with 0 units. This showed a similar independent effect of clopidogrel (OR, 2.0; 95% CI, 1.7-2.5; P < .001; Table IV ). Again, aspirin use had no effect.
Additional multivariable models were then constructed from the entire LEB cohort for major cardiac events, respiratory complications, and in-hospital mortality. For major cardiac events, there was an incrementally increased risk associated with an increasing VSG-CRI score category (Table V) . Independent of this and other cardiac risk factors, clopidogrel was found to be associated with major cardiac events (OR, 1.2; 95% CI, 1.0-1.5; P ¼ .05). Similarly, clopidogrel use was independently associated with increased respiratory complications (OR, 1.4; 95% CI, 1.0-2.0; P ¼ .03; Table VI ). There was also a trend toward increased in-hospital mortality associated with clopidogrel use, although this was not statistically significant (OR, 1.4; 95% CI, 0.9-2.1; P ¼ .2).
Impact of blood transfusion on secondary outcomes. To determine whether blood transfusion was affecting the association between clopidogrel and secondary outcomes, we first determined whether there was an association between discrepant secondary outcomes and blood transfusion. These analyses were performed for major cardiac events and respiratory complications because differences were associated with clopidogrel use in univariate and multivariable analysis.
Occurrence of major cardiac events was found to increase incrementally with increasing blood transfusion: 4.2% for 0 units, 11.6% for 1-2 units, and 20.4% for >2 units (P < .001 for trend; Fig) . Similarly, respiratory complications increased with increasing blood transfusion: 0.5% for 0 units, 3.1% for 1-2 units, and 8.8% for >2 units (P < .001 for trend).
Because these data implicated blood transfusion as an important mediator of worse secondary outcomes, we performed further stratified analyses using MantelHaenszel methods. Major cardiac events were more common among patients taking clopidogrel (8.8% vs 6.5%; P < .001) with an unweighted OR of 1.4 (Table VII) . However, stratification by blood transfusion amount demonstrated an increasing amount of major cardiac events in both groups. After stratification, a combined OR was 1.1 (P ¼ .4), indicating that clopidogrel had no effect on major cardiac events after controlling for blood transfusion amount.
Similarly, clopidogrel use was associated with respiratory complications on univariate analysis (2.5% vs 1.6%; P ¼ .007; unweighted OR, 1.6). Stratification by blood transfusion amount revealed an increasing rate of respiratory complications in both groups as well. The combined OR was 1.0 (P ¼ 1.0), indicating no effect of clopidogrel on respiratory complications after controlling for blood transfusion.
Using similar methods, we performed a stratified analysis to determine whether the association of clopidogrel with blood transfusion could be attributed to center-level differences in perioperative clopidogrel management. Patients taking clopidogrel received at least 1-unit blood transfusion in 38% of cases compared with 23% in patients not taking clopidogrel (unweighted OR, 2.0; P < .001). After dividing centers into terciles based on clopidogrel use at the time of surgery, we found that increased rates of blood transfusion persisted despite stratification (combined OR, 1.9; Supplementary Table, online only). 
DISCUSSION
In this analysis of nearly 10,000 patients undergoing LEB, clopidogrel use was independently associated with higher operative blood loss and perioperative blood transfusion. Clopidogrel use was also associated with increased rates of major cardiac events and respiratory complications. However, stratified analyses suggest that cardiac and respiratory complications were related to higher blood transfusion rates associated with clopidogrel use.
These results are consistent with our earlier report on roughly 3000 LEBs from the Vascular Study Group of New England, in which no difference in reoperation for bleeding was seen when patients were analyzed on the basis of antiplatelet medication use. 2 In contrast to this report, however, we have demonstrated that clopidogrel use is associated with increased blood loss and blood transfusions. It is apparent that the VQI's larger study population has facilitated the detection of these differences. [12] [13] [14] [15] [16] [17] [18] it has become increasingly clear that clopidogrel is associated with bleeding complications. Compared with LEB, bleeding after CEA is less likely to be associated with transfusion and more likely to lead to reoperation because of the severe consequences of ongoing blood loss. In our previous work, reoperation for bleeding was nearly twice as high in propensity-matched CEA patients taking aspirin and clopidogrel compared with those taking aspirin alone (1.3% vs 0.7%; P ¼ .004). 19 However, a lower associated rate of thrombotic complications led to an overall protective effect of dual antiplatelet therapy in patients undergoing CEA. In the current study, LEB patients also had higher rates of bleeding complications, but this occurred without any offsetting benefit. Therefore, the overall effect was detrimental to patients. The bleeding risk associated with clopidogrel in LEB patients may persist over time, but some patients with prosthetic grafts may achieve improved outcomes with dual antiplatelet therapy. Using a longer follow-up period, the clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial randomized 851 patients undergoing LEB to initiate aspirin or aspirin and clopidogrel 2 to 4 days after the procedure. 3 The primary safety end point was severe bleeding, which was defined by the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) classification. 20 In this system, bleeding events are classified as severe (intracranial hemorrhage or bleeding with hemodynamic compromise), moderate (blood transfusion in hemodynamically stable patients), or mild (no transfusion required). In the follow-up period, there were no differences in severe bleeding based on clopidogrel, but there were increased rates of mild and moderate bleeding. Overall, 16.7% of patients taking clopidogrel had a bleeding event compared with 7.1% of patients receiving placebo (P < .001). This suggests that the occurrence of bleeding events and blood transfusion in patients taking clopidogrel persists beyond the perioperative period. Some may interpret "moderate" bleeding complications as bearing little clinical significance. In addition, there is wide variation with regard to how freely patients undergoing LEB are administered blood transfusions, indicative of variable estimation of clinical risks and benefits associated with transfusion. 4 However, multiple studies have illustrated that vascular surgery patients who receive blood transfusions incur a variety of inferior outcomes. A previous report from the Vascular Study Group of New England demonstrated that perioperative blood transfusion was associated with increased wound infection and graft thrombosis after LEB. 5 A larger study using the VQI revealed that blood transfusion >2 units was an important predictor of surgical site infection. 8 Beyond infectious complications, blood transfusions appear to be associated with higher mortality as well as with poor cardiovascular and respiratory perioperative outcomes. Of nearly 9000 lower extremity revascularizations studied in the National Surgical Quality Improvement Program, the transfusion rate varied from 14.5% to 27.1%, depending on the procedure type. 6 After adjustment for transfusion propensity and other risk factors, blood transfusion was predictive of overall mortality, sepsis/shock, pulmonary complications, and return to operating room. Similarly, the study of patients undergoing major vascular surgery in the Michigan consortium also found that blood transfusion was independently associated with death, myocardial infarction, and pneumonia, 4 and a Dutch report showed that transfusions were associated with worse cardiovascular outcomes and mortality. 7 Similar to these reports, our data show that the higher rate of blood transfusions received by patients undergoing LEB taking clopidogrel coincide with higher rates of cardiac and respiratory complications. We cannot conclude, on the basis of these analyses, that clopidogrel use and associated increased blood transfusions cause these complications directly. However, we believe this powerful association deserves further study as it may have important implications for care of patients.
This study has several limitations. First, the timing of blood transfusion in relation to surgery cannot be determined. As a result, some transfusions may not have been related to bleeding. However, the concurrence of blood transfusions with high EBL suggests that many transfusions were related to perioperative bleeding complications. Second, wound hematoma formation that did not require blood transfusion cannot be determined in this study. This is another important outcome that may predispose patients to surgical site infection. Third, the indication for clopidogrel use is not known but likely indicates a population of patients with higher cardiac risk. This is likely to be representative of selection bias. To account for this, cardiac comorbidities, characterized by the VSG-CRI, were used to control for preoperative cardiac risk in determining the effect of clopidogrel on 
CONCLUSIONS
Perioperative clopidogrel is associated with increased operative blood loss and blood transfusions at the time of LEB but not increased rates of reoperation for bleeding. Patients receiving clopidogrel also have higher rates of major cardiac events and inferior respiratory outcomes, which may be attributable to increased rates of blood transfusion. On the basis of these findings from a large national registry, surgeons should consider discontinuation of perioperative clopidogrel at the time of LEB when it is clinically appropriate. Furthermore, the clinical consequences of perioperative blood transfusion merit further study. 
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